NovoCure (NVCR) files 8-K with Q2 2025 results press release

NovoCure Limited reported that it issued a press release announcing certain financial results for the quarter ended June 30, 2025.

Rhea-AI Filing Summary

NovoCure Limited reported that it issued a press release announcing certain financial results for the quarter ended June 30, 2025. The announcement was furnished in an 8-K dated October 30, 2025.

The press release is provided as Exhibit 99.1.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did NovoCure (NVCR) disclose in this 8-K?

NovoCure stated it issued a press release announcing certain financial results for the quarter ended June 30, 2025, furnished as Exhibit 99.1.

Which period do the announced results cover for NVCR?

The results cover the quarter ended June 30, 2025.

Where can I find the detailed numbers mentioned by NovoCure?

Details are included in the press release attached as Exhibit 99.1.

What is NovoCure’s trading symbol and exchange?

NovoCure’s ordinary shares trade under NVCR on The Nasdaq Stock Market LLC.

When was the announcement made?

The company reported the announcement in an 8-K dated October 30, 2025.

Does the 8-K include financial statements?

The filing furnishes a press release as Exhibit 99.1; no additional financial statements are listed in the excerpt.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/30/2025 - 06:59 AM Learn about SEC filing dates

0001645113false00016451132025-07-162025-10-31

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

October 30, 2025

Date of Report (date of earliest event reported)

NovoCure Limited

(Exact name of registrant as specified in its charter)

Jersey			001-37565						98-1057807
(State or other jurisdiction of incorporation or organization)			(Commission File Number)						(I.R.S. Employer Identification No.)
No. 4 The Forum, Grenville Street			St. Helier			Jersey			JE2 4UF
(Address of Principal Executive Offices)									(Zip Code)

+44 (0) 15 3475 6700

Registrant's telephone number, including area code

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Ordinary Shares, no par value			NVCR			The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

o

Item 2.02     Results of Operations and Financial Condition.

On October 30, 2025, the Company issued a press release announcing certain financial results for the quarter ended

June 30, 2025. A copy of the press release is attached as Exhibit 99.1.

Item 9.01    Financial Statements and Exhibits.

(d)    Exhibits

Exhibit No.			Description
99.1			Press Release of NovoCure Limited, dated October 30, 2025
104			Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NovoCure Limited

(Registrant)

Date: October 30, 2025

By: /s/ Christoph Brackmann  

Name: Christoph Brackmann

Title: Chief Financial Officer